The ALB Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-mediated gene disruption product in which the human ALB locus has been targeted to generate a heterogeneous polyclonal knockout population. This cell pool offers a loss-of-function model for studying albumin biology without the need for clonal isolation, providing a robust platform for experimental workflows requiring population-level responses. By eliminating endogenous albumin expression, researchers can dissect the protein??s roles in molecular transport, drug binding, and colloid osmotic pressure regulation.
The 143B host cell line is a well-characterized human osteosarcoma model widely employed in cancer research, bone biology, and drug discovery. Derived from a bone malignancy, these cells exhibit rapid proliferation and a transformed phenotype, making them amenable to genetic manipulation and functional assays. Although 143B cells do not normally express albumin at physiologically relevant levels, the knockout serves as a stringent negative control and permits ectopic expression studies to explore albumin??s functions in a non-hepatic context.
The ALB gene encodes serum albumin, a 66.5 kDa protein and the most abundant plasma component, responsible for maintaining oncotic pressure and transporting a diverse array of ligands including fatty acids, hormones, and xenobiotics. Albumin transcription is regulated by hepatic nuclear factors such as HNF1-alpha and C/EBP-beta, and is modulated by insulin, glucocorticoids, and the JAK/STAT pathway via STAT3. Functionally, albumin interacts directly with long-chain fatty acids, bilirubin, thyroxine, and drugs like warfarin, serving as a critical determinant of pharmacokinetics. The albumin promoter integrates signals from HNF4A, C/EBP-alpha, and the glucocorticoid receptor to drive expression, while downstream effects include sustaining plasma oncotic pressure and facilitating systemic transport of small molecules.
In the 143B osteosarcoma background, ALB knockout provides a unique tool to investigate albumin-dependent processes in the absence of hepatocyte-specific machinery. When combined with ectopic expression of hepatic transcription factors or differentiation protocols, these cells can be used to dissect the requirements for albumin production and secretion. Conversely, the knockout population serves as an ideal negative control in hepatocyte-like differentiation studies and enables precise analysis of how albumin influences drug sensitivity and fatty acid uptake in a tumor microenvironment setting. This model thus bridges cancer biology and hepatic physiology, offering insights into how albumin loss may affect osteosarcoma progression or therapeutic response.
Typical research applications include albumin-dependent drug uptake assays, where knockout cells help define albumin??s contribution to intracellular drug accumulation, and secretion pathway studies exploiting the secretory pathway machinery of 143B cells. These polyclonal knockout cells are also valuable in hepatocyte-like differentiation controls, allowing researchers to benchmark the acquisition of hepatocytic functions, and in transporter interaction studies to parse albumin-mediated versus direct transport. Common downstream assays for characterizing this model include western blotting, RT-qPCR, ELISA, fatty acid uptake assays, and drug sensitivity tests, each providing orthogonal measures of knockout efficacy and functional consequences. For further information or to acquire this ALB knockout cell population, please contact Ascent Research.
